Sun Pharma Freezes Generic Eloxatin Sales

Law360, New York (February 11, 2011, 1:23 PM EST) -- Sun Pharmaceutical Industries Inc. has agreed to temporarily halt its sales of oxaliplatin, the active ingredient in Sanofi-Aventis US LLC’s colon cancer drug Eloxatin, as the parties decide how to proceed with their revived patent infringement dispute.

Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey on Wednesday signed off on the parties' stipulation and proposed order requiring Sun and its subsidiary Caraco Pharmaceutical Laboratories Inc. to refrain from selling, attempting to sell or offering for sale any product containing...
To view the full article, register now.